E2 ModeratePreliminaryPEM ?ObservationalPeer-reviewedMachine draft
Epipharyngeal Abrasive Therapy (EAT) Has Potential as a Novel Method for Long COVID Treatment.
Imai, Kazuaki, Yamano, Takafumi, Nishi, Soichiro et al. · Viruses · 2022 · DOI
Quick Summary
This study tested a Japanese treatment called epipharyngeal abrasive therapy (EAT) on 58 long COVID patients. The treatment involves applying zinc chloride to the back of the throat to reduce inflammation. Patients received weekly treatments for one month, and three common symptoms—fatigue, headaches, and difficulty concentrating—improved significantly after treatment.
Why It Matters
This research is relevant to ME/CFS because long COVID and ME/CFS share overlapping symptoms including post-exertional malaise, fatigue, and cognitive dysfunction. If epipharyngeal inflammation contributes to these conditions, a targeted anti-inflammatory approach could offer a new therapeutic avenue for symptom management in both populations.
Observed Findings
- All 58 long COVID patients in the study had detectable residual inflammation in the epipharynx
- Fatigue intensity significantly decreased after EAT treatment
- Headache intensity significantly decreased after EAT treatment
- Attention disorder intensity significantly decreased after EAT treatment
Inferred Conclusions
- Epipharyngeal inflammation may be a common feature in long COVID pathophysiology
- EAT shows potential as a novel treatment approach for long COVID symptoms
- Symptoms overlapping with ME/CFS may improve through epipharyngeal-targeted therapy
Remaining Questions
- What is the optimal dosing schedule and duration of EAT, and do effects persist after treatment cessation?
- How does EAT compare to placebo or standard care in a randomized controlled trial?
- Which long COVID patients are most likely to respond to EAT, and what baseline characteristics predict treatment success?
- Can objective biomarkers of epipharyngeal inflammation be used to monitor treatment response and predict clinical outcomes?
What This Study Does Not Prove
This study does not prove that EAT is an effective long COVID or ME/CFS treatment because it lacks a control group and relies on subjective symptom reporting without objective biomarkers. The improvement in symptoms could reflect placebo effect, natural recovery, or other confounding factors. Results cannot be generalized beyond the specific population studied, and long-term efficacy remains unknown.
Tags
Symptom:Cognitive DysfunctionFatigue
Phenotype:Infection-TriggeredLong COVID Overlap
Method Flag:PEM Not DefinedWeak Case DefinitionNo ControlsSmall SampleExploratory Only
Metadata
- DOI
- 10.3390/v14050907
- PMID
- 35632649
- Review status
- Machine draft
- Evidence level
- Single-study or moderate support from human research
- Last updated
- 8 April 2026